Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, adenoma, benign urinary system neoplasm, epithelial neoplasm, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, lung disorder, lung neoplasm, malignant mesothelioma, malignant pleural mesothelioma, mesothelial neoplasm, mesothelioma, mixed neoplasm, neoplasm, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm, urinary system disorder	Recruiting	Phase 1 / Phase 2	2026-06-05		NCT05765084

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Algemeen Ziekenhuis Maria Middelares	18
Kom Op Tegen Kanker	20
Roche Pharma AG	59
University Hospital, Antwerp	108
Vitaz	5

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Antwerp University Hospital	Edegem	Belgium	18
AZ Maria Middelares	Ghent	Belgium	44
Vitaz	Sint-Niklaas	Belgium	27